EFFICACY AND SAFETY OF INTRAVENOUS AND ORAL PROPAFENONE IN PEDIATRIC CARDIAC DYSRHYTHMIAS
EFFICACY AND SAFETY OF INTRAVENOUS AND ORAL PROPAFENONE IN PEDIATRIC CARDIAC DYSRHYTHMIAS
复制标题
DOI：
10.1016/0002-9149(91)90646-3
复制
发表时间：
1991-09-15
影响因子：
2.8
通讯作者：
KALLFELZ, HC
中科院分区：
文献类型：
--
作者：
REIMER, A;PAUL, T;KALLFELZ, HC
普罗帕酮用于58例患者，平均年龄为3.2岁（范围0.1 - 16岁）。 平均静脉给药剂量为1.2 mg/kg体重（范围0.3 - 1.5 mg）。 最终平均经口维持剂量为308 mg/m2体表面积（范围200 - 600 mg/m2，16.8 mg/kg体重）。 静脉应用普罗帕酮后，36例患者中有21例有效，15例心房扑动转复，25例患者中有15例折返性室上性心动过速得到控制。 普罗帕酮对4例混乱型房性心动过速中3例部分或完全有效。 2例婴儿的交界性异位心动过速被抑制。 37名患者接受口服治疗，平均随访2.2年。 普罗帕酮对37例患者中的33例（89%）有效; 2例患者的房扑得到控制，1例患者的心室异位得到抑制。 心律平对折返性室上性心动过速有效25例。 3例混乱型房性心动过速和2例交界性异位心动过速经静脉治疗后均得到控制，全身不良反应少见。 2例患者发生心律失常，1例法洛四联症修补术后心室异位患者在普罗帕酮维持治疗期间猝死。
Propafenone was administered to 58 patients with a mean age of 3.2 years (range 0.1 to 16). Mean intravenous dose was 1.2 mg/kg body weight (range 0.3 to 1.5 mg). The final mean oral maintenance dose was 308 mg/m2 body surface area (range 200 to 600 mg/m2, 16.8 mg/kg body weight). After intravenous application, propafenone was effective in 21 of 36 patients; atrial flutter was converted in 1 to 5 patients, and reentry supraventricular tachycardia was controlled in 15 of 25 patients. Propafenone was partially or completely effective in 3 of 4 patients with chaotic atrial tachycardia. Junctional ectopic tachycardia was suppressed in 2 infants. Thirty-seven patients had oral treatment with a mean follow-up of 2.2 years. Propafenone was effective in 33 of 37 patients (89%); atrial flutter was controlled in 2 patients, ventricular ectopy was suppressed in 1 of 2 patients. In reentry supraventricular tachycardia, propafenone was effective in 25 of 28 patients. Chaotic atrial tachycardia (n = 3) and junctional ectopic tachycardia (n = 2) were controlled after successful intravenous therapy.Systemic side effects were rare. Two patients developed a proarrhythmic effect, and 1 patient with ventricular ectopy after repair of tetralogy of Fallot died suddenly during propafenone maintenance therapy.